News & Updates
Filter by Specialty:
RA remission rates higher with abatacept, certolizumab pegol vs conventional therapy
In the treatment of rheumatoid arthritis (RA), more patients achieve clinical remission with abatacept or certolizumab pegol, but not with tocilizumab, than with active conventional therapy, according to a study.
RA remission rates higher with abatacept, certolizumab pegol vs conventional therapy
17 Jul 2023
SGLT2 inhibitors tied to kidney benefits, reduced MACE risk
Treatment with sodium-glucose lowering co-transporter 2 inhibitors (SGLT2i) helps arrest the decline in estimated glomerular filtration rate (eGFR) and is associated with a lower risk of adverse kidney events among adults with diabetes, irrespective of baseline albuminuria status, as shown in a study presented at the recent ADA 2023.
SGLT2 inhibitors tied to kidney benefits, reduced MACE risk
17 Jul 2023
Bezlotoxumab prevents CDI recurrence in immunocompromised patients
Treatment with bezlotoxumab results in a significant decrease in recurrent Clostridioides difficile infection (CDI) in a cohort of immunocompromised patients and transplant recipients, reports a study.
Bezlotoxumab prevents CDI recurrence in immunocompromised patients
16 Jul 2023
Time to recovery from COVID-19 pneumonia similar for abatacept, cenicriviroc, infliximab
Time to recovery from COVID-19 pneumonia does not appear to differ following treatment with abatacept, cenicriviroc, or infliximab among hospitalized patients, according to a study.
Time to recovery from COVID-19 pneumonia similar for abatacept, cenicriviroc, infliximab
15 Jul 2023
Danuglipron helps with glucose control, weight loss in T2D
The glucagon-like peptide 1 receptor (GLP-1R) agonist danuglipron appears to be beneficial in the treatment of patients with type 2 diabetes (T2D), yielding reductions in glycated haemoglobin (HbA1c), fasting plasma glucose (FPG), and body weight, without fasting restrictions, as shown in the results of a phase IIb study.
Danuglipron helps with glucose control, weight loss in T2D
15 Jul 2023
Long-acting ART induces viral suppression in people with HIV
People with HIV (PWH) who are treated with long-acting (LA) antiretroviral therapy (ART) achieve virologic suppression, as do those with viraemia and challenges to adherence, reports a study.